Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24077359 | 0.93 | NLRP3 (0.59) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL24077192 | 0.93 | NLRP3 (0.59) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL24076954 | 0.92 | NLRP3 (0.58) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL24076426 | 0.92 | NLRP3 (0.58) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL30168566 | 0.91 | NLRP3 (0.57) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL24076366 | 0.91 | NLRP3 (0.57) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL25749470 | 0.90 | NLRP3 (0.55) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL25748603 | 0.90 | NLRP3 (0.61) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL25748626 | 0.90 | NLRP3 (0.61) | NLRP3GRIN1GRIN2BGPR139AKR1B1 | |
| SCHEMBL24076299 | 0.89 | NLRP3 (0.53) | NLRP3GRIN1GRIN2BGPR139AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885GRIN1 567/4885GRIN2B 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.